JPRN-jRCT1032220559
Not yet recruiting
未知
Exploratory analysis of liquid biopsy for the predictive factors associated with outcome of PD-1 Pathway Blockade in Multicenter Study - MRD-PD1 study
Ohe Yuichiro0 sites100 target enrollmentJanuary 7, 2023
Conditionsnon-small cell lung cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- non-small cell lung cancer
- Sponsor
- Ohe Yuichiro
- Enrollment
- 100
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who meet the eligibility criteria of the most recent JCOG 1701 (to confirm the non\-inferiority of survival of discontinuation of PD\-1 pathway inhibitors versus their continuation in patients with advanced or recurrent non\-small\-cell lung cancer who have had no reccurence to PD\-1 pathway inhibitors for 12 months or longer) protocol and who are not participating in JCOG 1701
- •Patients who have given their written consent to participate in this study
- •Patients who are able to provide tumor tissue samples necessary for the study
Exclusion Criteria
- •Patients who do not meet the eligibility criteria in the most recent JCOG1701 protocol or are currently participating in JCOG1701
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Exploratory research of liquid biopsy for patients with cancercancerJPRN-UMIN000033269Cancer Precision Medicine Center Cancer Institute,800
Completed
Not Applicable
Investigation on the usefulness of liquid biopsy for tumor-derived circulating DNA in patients with EGFR-mutant NSCLC during and after treatment with EGFR-TKIson-small cell Lung CancerJPRN-UMIN000023248PHRF122
Recruiting
Not Applicable
Validation process of liquid biopsy for solid tumorsHealth Condition 1: D499- Neoplasm of unspecified behavior of unspecified siteCTRI/2023/03/050258Cancer Research and Statistic Foundation CRSF
Active, not recruiting
Phase 1
tility of analysis in blood of the evolution of the drug brigatinib for patients with lung cancer with ALK mutationsALK+ non-small cell lung cancerMedDRA version: 20.0Level: LLTClassification code: 10025055Term: Lung cancer non-small cell stage IV Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2024-511317-38-00Fundacion GECP33
Active, not recruiting
Phase 1
tility of analysis in blood of the evolution of the drug brigatinib for patients with lung cancer with ALK mutationsALK+ non-small cell lung cancerMedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-002369-36-ESFundación GECP30